Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Aeglea Biothera Cmn (AGLE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 60,525
  • Shares Outstanding, K 13,450
  • Annual Sales, $ 4,630 K
  • Annual Income, $ -21,700 K
  • 36-Month Beta N/A
  • Price/Sales 12.88
  • Price/Cash Flow 0.00
  • Price/Book 1.04

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.26 +5.63%
on 05/26/17
7.28 -38.19%
on 05/01/17
-2.45 (-35.25%)
since 04/26/17
3-Month
4.26 +5.63%
on 05/26/17
8.14 -44.72%
on 03/20/17
-1.33 (-22.81%)
since 02/24/17
52-Week
3.66 +22.95%
on 01/31/17
10.34 -56.48%
on 11/21/16
-2.95 (-39.60%)
since 05/26/16

Most Recent Stories

More News
Bristol-Myers' Opdivo Gets Priority Review for Liver Cancer

Bristol-Myers Squibb Company (BMY) announced that the FDA has accepted and granted a priority review designation to the supplemental Biologics License Application for the label expansion of Opdivo to patients...

AGLE : 4.50 (+1.58%)
VVUS : 1.13 (+0.89%)
MEIP : 2.12 (+7.61%)
BMY : 53.97 (-0.77%)
Achaogen's Plazomicin Gets Breakthrough Therapy Designation

Achaogen, Inc. (AKAO) announced that the FDA granted Breakthrough Therapy designation for plazomicin, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant...

AGLE : 4.50 (+1.58%)
VVUS : 1.13 (+0.89%)
AKAO : 21.64 (-1.99%)
MEIP : 2.12 (+7.61%)
Aeglea BioTherapeutics Provides AEB1102 Program and Corporate Update

--Announces three single agent expansion arms for AEB1102 solid tumor trials--

AGLE : 4.50 (+1.58%)
Shire (SHPG) Up on Positive Phase III Study Data on HAE Drug

Shire plc (SHPG) announced positive top-line results from the phase III study, HELP, on HAE candidate, lanadelumab.

AGLE : 4.50 (+1.58%)
VVUS : 1.13 (+0.89%)
SHPG : 177.18 (-4.13%)
PFE : 32.14 (-0.06%)
Valeant (VRX) Decides to Extend Stay on Xifaxan's ANDA

Valeant Pharmaceuticals International, Inc. (VRX) announced that it has decided to stay outstanding litigation and extend the 30-month stay regarding Teva's ANDA for a generic version of Xifaxan 550 mg...

AGLE : 4.50 (+1.58%)
VVUS : 1.13 (+0.89%)
TEVA : 28.50 (-0.73%)
VRX : 12.83 (+0.31%)
Vertex Ups Kalydeco Sales View as FDA Okays Label Expansion

Vertex Pharmaceuticals Incorporated???s (VRTX) announced that the FDA has approved its lead marketed drug, Kalydeco (ivacaftor) for expanded use.

AGLE : 4.50 (+1.58%)
VVUS : 1.13 (+0.89%)
VRTX : 119.92 (+1.11%)
MEIP : 2.12 (+7.61%)
Alexion's (ALXN) Strensiq Results Positive in Long-Term Study

Alexion Pharmaceuticals, Inc. (ALXN) announced that researchers presented encouraging data on Strensiq at the European Calcified Tissue Society (ECTS) Congress in Austria.

AGLE : 4.50 (+1.58%)
VVUS : 1.13 (+0.89%)
MEIP : 2.12 (+7.61%)
ALXN : 97.70 (-0.81%)
Kamada (KMDA) Posts Q1 Loss Wider than Expected, Sales Miss

Kamada Ltd. (KMDA) reported adjusted loss of 11 cents in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 3 cents.

AGLE : 4.50 (+1.58%)
VVUS : 1.13 (+0.89%)
MEIP : 2.12 (+7.61%)
KMDA : 7.15 (+0.70%)
Cardiome (CRME) Q1 Loss Wider Than Expected, Sales Miss

Cardiome Pharma Corp. (CRME) reported loss of 20 cents per share in first quarter of 2017. Reported loss is wider than both the Zacks Consensus Estimate of a loss of 15 cents and year-ago loss of 9 cents....

AGLE : 4.50 (+1.58%)
VVUS : 1.13 (+0.89%)
AGN : 223.12 (-0.55%)
CRME : 4.33 (+4.84%)
Reasons to Add Puma Biotechnology (PBYI) to Portfolio Now

On May 16, 2017, we issued an updated report on Puma Biotechnology, Inc. (PBYI).

AGLE : 4.50 (+1.58%)
VVUS : 1.13 (+0.89%)
PBYI : 79.75 (+2.18%)
MEIP : 2.12 (+7.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Aeglea BioTherapeutics, Inc. is a biotechnology company which is engaged in developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. Its portfolio of products consists of AEB1102, AEB3103, AEB2109 and AEB4104 which are in different clinical...

See More

Support & Resistance

2nd Resistance Point 4.79
1st Resistance Point 4.65
Last Price 4.50
1st Support Level 4.31
2nd Support Level 4.11

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.